Firm Submits Clinical Protocol for IRB Approval for Phase 3 COVID-19 Trial
Source: Streetwise Reports  (8/28/20)
Revive Therapeutics reported it submitted the clinical protocol for independent Institutional Review Board approval for its Phase 3 study of Bucillamine in COVID-19. More >

VBI Shares Climb 34% After Identifying Two One-Dose COVID-19 Vaccine Candidates
Source: Streetwise Reports  (8/27/20)
VBI Vaccines shares traded higher after the company reported preclinical coronavirus program data and selection of clinical candidates with potential as one-dose vaccines. More >

CytoDyn Receives the UK's MHRA Approval for Phase 3 COVID-19 Study
Source: Streetwise Reports  (8/24/20)
CytoDyn Inc. shares traded higher after the company reported it received authorization from the U.K.'s MHRA to proceed with its Phase 3 study of leronlimab in patients with severe-to-critical COVID-19. More >

CureVac Shares Rise on Talks with EC to Supply 405 Million mRNA-Based COVID-19 Vaccine Doses
Source: Streetwise Reports  (8/20/20)
CureVac NV shares traded 13% higher after the company reported it is in advanced discussions with the European Commission to supply up to 405 million doses of a potential mRNA-based COVID-19 vaccine. More >

Biotech Releases Positive Interim Results from Cystic Fibrosis Study
Source: Streetwise Reports  (8/19/20)
This and other recent key events of AzurRx BioPharma are recapped in a ROTH Capital Partners report. More >

California Biopharma to be Acquired by Sanofi for $3.6 Billion
Source: Streetwise Reports  (8/19/20)
The deal is summarized and Principia Biopharma's Q2/20 clinical achievements are recapped in an H.C. Wainwright & Co. report. More >

Momenta Pharmaceuticals Shares Rise 69% on $6.5 Billion Johnson & Johnson Takeover Bid
Source: Streetwise Reports  (8/19/20)
Shares of Momenta Pharmaceuticals set a new 52-week high after the company reported it entered into a definitive agreement with Johnson & Johnson to be acquired for $52.50 per share in cash. More >

Pharmaceutical Firm Enrolls First US Patient in Phase 2b/3 Ifenprodil COVID-19 Trial
Source: Streetwise Reports  (8/17/20)
Algernon Pharmaceuticals reported it has enrolled the first U.S. patient in its multinational Phase 2b/3 human study of Ifenprodil for use in treatment of SARS-CoV-2. More >

Canadian Biotech Advances Antibodies, Diagnostics Programs in Q2/20
Source: Streetwise Reports  (8/14/20)
One highlight is ProMIS Neurosciences' development of a SARS CoV-2 antibody test. More >

Mesoblast Shares Rocket Higher as FDA Committee Votes in Favor of Remestemcel-L for Pediatric SR-aGVHD Patients
Source: Streetwise Reports  (8/14/20)
Shares of Mesoblast Ltd. traded 50% higher after the company reported that the U.S. FDA's Oncologic Drugs Advisory Committee voted nine to one in favor of remestemcel-L (RYONCILâ„¢) for efficacy in children with steroid-refractory acute graft versus host disease. More >

Life Sciences Firm Signs MOU for Phase 3 COVID-19 Study
Source: Streetwise Reports  (8/14/20)
Revive Therapeutics reported it signed a MOU with Attwill Medical Solutions Sterilflow to be a clinical packaging and distribution resource for its Phase 3 clinical trial of Bucillamine in COVID-19. More >

Biotech Develops Oral Film Strips for Psychedelic Medicine Delivery
Source: Streetwise Reports  (8/12/20)
This development is a technical milestone for Revive Therapeutics and its drug delivery technology. More >

Eyenovia Shares Look 38% Higher on Development Deal with Arctic Vision in Asia
Source: Streetwise Reports  (8/11/20)
Shares of Eyenovia Inc. set a new 52-week high after the firm reported it entered into an exclusive collaboration and license agreement with Arctic Vision to develop and market MicroPine and MicroLine in China and South Korea. More >

Seres Therapeutics Shares Go Parabolic on Positive Topline Data from Phase 3 C.Diff Trial
Source: Streetwise Reports  (8/10/20)
Seres Therapeutics shares traded 350% higher setting a new 52-week high after the firm reported positive topline results from its SER-109 Phase 3 ECOSPOR III study in recurrent C. difficile infection. More >

Is Summit's Ridinilazole a Threat to Acurx's Ibezapolstat in the C.difficile Space?
Source: Dr. KSS, MD, PhD, for Streetwise Reports  (8/10/20)
Dr. KSS, the founder and editor-in-chief of BioPub.co, compares the two drugs as potential treatments for C. difficile. More >

Pharmaceutical Firm Doses First Patient in Phase 2 IPF and Chronic Cough Trial
Source: Streetwise Reports  (8/8/20)
Algernon Pharmaceuticals reported that the first patient has been dosed in the Phase 2 human study of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough. More >

Biopharma Preparing to Initiate Phase 3 COVID-19 Trial
Source: Streetwise Reports  (8/7/20)
Revive Therapeutics is now "finalizing agreements and aligning resources to initiate the Phase 3 clinical trial in September." More >

Denali Shares Rise 37% on Advancement of DNL151 into Late Stage Parkinson's Trials
Source: Streetwise Reports  (8/6/20)
Shares of Denali Therapeutics reached a new 52-week high after the company reported plans to advance DNL151 in two separate late stage Parkinson's disease clinical studies with its partner Biogen. More >

Biopharma Gets FDA Approval for Phase 3 COVID-19 Trial
Source: Streetwise Reports  (8/4/20)
Revive Therapeutics' trial will test Bucillamine in patients with mild to moderate COVID-19. More >

Ten Good Reasons to Invest Now Pre-Market in Acurx Pharmaceuticals
Source: Dr. KSS, MD, PhD, for Streetwise Reports  (8/3/20)
Dr. KSS, the founder and editor-in-chief of BioPub.co, provides his investment thesis for a company that is promulgating the first new class of antibiotics in 30 years. More >

Kodak Shares Triple in a Flash on $765 Million Loan from DFC for New Pharmaceutical Unit
Source: Streetwise Reports  (7/28/20)
Eastman Kodak shares traded more than 200% higher after the company reported it is forming a new business unit to produce essential pharmaceutical components funded by the U.S. International Development Finance Corporation. More >

TCR2 Therapeutics Reports Positive Results in Mesothelin-Expressing Solid Tumor Study
Source: Streetwise Reports  (7/27/20)
Shares of TCR2 Therapeutics traded 30% higher after the firm released encouraging results from the Phase 1 portion of its clinical study of TC-210 in treating advanced mesothelin-expressing solid tumors.

More >

Milestone Shares More than Double After Presenting Updated Clinical Plan for Heart Condition
Source: Streetwise Reports  (7/23/20)
Shares of Milestone Pharmaceuticals traded 150% higher after the company reported regulatory guidance and updated its clinical development plan for etripamil nasal spray designed for self-administered use in PSVT treatment. More >

Biopharma's Therapeutic Jumps to Phase 2 Testing for COVID-19 'to Shut Down the Cytokine Storm'
Source: Streetwise Reports  (7/22/20)
A development update on Sorrento Therapeutics' three coronavirus-related products is provided in a Dawson James report. More >

Dynavax Shares Rise 20% on Partnership with Mount Sinai to Develop Universal Flu Vaccine
Source: Streetwise Reports  (7/17/20)
Shares of Dynavax Technologies reached a new 52-week high after the company reported that it is collaborating with Mount Sinai to develop a universal influenza vaccine candidate with CpG 1018 adjuvant. More >